Lynch syndrome finally has its own code

Four syndromes leave the catch-all

Until October 1, a patient with Lynch syndrome and a patient with a pathogenic BRCA2 mutation carried the same code. So did a patient with Li-Fraumeni. All of them landed in Z15.09, genetic susceptibility to other malignant neoplasm, alongside everything else the code set had no room for. Some labs and clinicians reached for Z15.01 on BRCA-positive results instead.

FY 2027 added category QA1 and gave four of them their own codes.

• Lynch syndrome · FY 2027 code: QA1.71 · Previously: Z15.09, or Z15.01 for BRCA in some settings
• Familial cancer syndrome, pathogenic BRCA1 mutation · FY 2027 code: QA1.790
• Familial cancer syndrome, pathogenic BRCA2 mutation · FY 2027 code: QA1.791
• Li-Fraumeni syndrome · FY 2027 code: QA1.792

Two things make this worth your attention beyond the specificity.

Risk adjustment. A catch-all code tells a payer almost nothing about a population. Four named syndromes tell them a great deal. If you manage risk-adjusted lives, your hereditary cancer cohort has been invisible in your own data, and now it is not.

The codes exist because clinicians asked for them. Fight CRC and CGA-IGC members ran a campaign for ICD-10 recognition of Lynch syndrome. They asked for five codes, one per gene. They got one. That is how the process works, and it is worth knowing if your organization has ever wanted a code that does not exist.

Keep family history separate. Z84.81 covers family history of a BRCA or Lynch-associated gene mutation, which is a different clinical fact from a patient's own confirmed mutation. Coding a confirmed carrier as family history undersells the patient and the population.

Confirm the exact code titles and placement against the CMS FY 2027 tabular before you configure anything. Two independent sources list these four, and one gives an effective date of September 2026 that conflicts with the October 1 code-set date.

While you are in that chapter , FY 2027 also added specificity to secondary malignant neoplasms: C78.31 larynx, C78.32 pharynx, C79.83 oral cavity. If your head-and-neck oncology notes have been landing on unspecified secondary sites, those three close the gap.

The CY 2027 Physician Fee Schedule final rule is still pending. The proposed rule published July 16 (91 FR 43842) and comments closed September 14. A final rule is expected around November 1.

What it does to your claims: nothing yet. Watch two proposals: paying the most expensive same-day service at 100% and additional same-day services at 50%, and replacing G2211 with a modifier carrying a 16% increase. Reconfigure nothing until the rule posts.

NCCI v33.0 test files expected next week. Around November 2, per trade coverage.

What it does to your claims: nothing on its own. Book the time now with whoever maintains your scrubber, because the change reports around November 17 are what actually need six weeks.

Medicare Advantage is where your exposure moved

Kodiak Solutions reports that Medicare Advantage plans showed higher initial and final denial rates than traditional Medicare, and more than double the rate of takebacks.

If your client mix or payer mix has shifted toward MA, and across this industry it has, your exposure grew even while your aggregate denial rate improved. An aggregate number averages a worsening payer class against a stable one and shows you the middle.

Run denials and takebacks by payer class before you report an improvement to a client or a board.

A new code only helps if the documentation that supports it reaches the coder.

Hereditary syndrome findings live in genetic counseling notes, outside lab reports and oncology consult letters. Three documents, often three systems, and the encounter being coded is frequently none of them. A coder working the visit in front of them has no way to know a confirmed BRCA2 mutation sits in a report from eleven months ago.

That is a context problem, and coder training does not touch it. Patient Chart Profile holds a patient's earlier charts and how they were coded, so the coder working today's encounter can see what was established before it. Every assigned code carries the chart passage it came from and the guideline behind it.

Pull every claim since October 1 carrying Z15.09 or Z15.01. For each, check whether the record names a specific syndrome. The ones that do belong in QA1 now, and the count tells you how much of your hereditary cancer population has been invisible in your own reporting.